Breaking News Instant updates and real-time market news.

2022-09-13 05:48:29 OTLY Oatly Group $3.30 / +0.035 (+1.07%) 05:48 09/13/22 09/13 05:48 09/13/22 05:48	Oatly Group downgraded to Neutral from Outperform at Credit Suisse Credit Suisse analyst Kaumil Gajrawala downgraded Oatly Group to Neutral from Outperform with a price target of $3.43, down from $6. The analyst expects a "particularly volatile consumer environment" in Europe and Asia. Inflation and "unpredictable lockdowns" have already hurt Oatly's ability to compete against peers with more capacity, Gajrawala tells investors in a research note. The analyst believes these headwinds will strengthen with colder months ahead, delaying the company's growth and margin story "yet again."

2022-09-13 05:48:29

OTLY

Oatly Group

$3.30 / +0.035 (+1.07%)

05:48

09/13/22

09/13

05:48

09/13/22

05:48

Oatly Group downgraded to Neutral from Outperform at Credit Suisse

Credit Suisse analyst Kaumil Gajrawala downgraded Oatly Group to Neutral from Outperform with a price target of $3.43, down from $6. The analyst expects a "particularly volatile consumer environment" in Europe and Asia. Inflation and "unpredictable lockdowns" have already hurt Oatly's ability to compete against peers with more capacity, Gajrawala tells investors in a research note. The analyst believes these headwinds will strengthen with colder months ahead, delaying the company's growth and margin story "yet again."

OTHER BREAKING NEWS FROM THE FLY

Recommendations	BP price target raised to 650 GBp from 550 GBp at RBC Capital » 09:18 02/08/23 02/08 09:18 02/08/23 09:18 BP BP $37.73 / +2.91 (+8.36%) RBC Capital analyst Biraj… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options BP BP $37.73 / +2.91 (+8.36%) 02/07/23 BP aims for $51B-$56B group EBITDA in 2023 02/07/23 BP sees FY23 CapEx $16B-$18B 01/17/23 Tritium says BP has placed largest order in company history 01/04/23 BP increases investment in onshore U.S. oil and gas to $2.4B in 2023 BP BP $37.73 / +2.91 (+8.36%) 06:25 Today Bernstein BP price target raised to $53 from $48 at Bernstein 02/07/23 TD Securities BP upgraded to Buy from Hold at TD Securities 01/23/23 Morgan Stanley BP price target raised to 636 GBp from 603 GBp at Morgan Stanley 01/19/23 JPMorgan BP price target lowered to 540 GBp from 560 GBp at JPMorgan BP BP $37.73 / +2.91 (+8.36%) 02/07/23 BP reports Q4 EPS $1.59, consensus $1.67 11/01/22 BP reports Q3 EPS $2.59, consensus $1.94 BP BP $37.73 / +2.91 (+8.36%) 01/18/23 U.S. Energy Secretary warns GOP of oil bill risks, Reuters says 01/10/23 ExxonMobil led group develops1.3B barrel off shore Guyana field, AP reports 12/05/22 BP bets big on hydrogen as fuel of the future, Reuters reports 12/04/22 OPEC+ keeps oil curbs despite Russia price cap, WSJ reports BP BP $37.73 / +2.91 (+8.36%) 02/07/23 What You Missed On Wall Street On Tuesday 02/07/23 What You Missed On Wall Street This Morning 12/05/22 What You Missed On Wall Street On Monday 12/05/22 What You Missed On Wall Street This Morning BP BP $37.73 / +2.91 (+8.36%) 01/20/23 Unusually active option classes on open January 20th 01/09/23 $600k upside call Seller in BP 12/16/22 Unusually active option classes on open December 16th 11/28/22 BP put volume heavy and directionally bearish
Recommendations	Inspire Medical price target raised to $305 from $250 at Lake Street » 09:17 02/08/23 02/08 09:17 02/08/23 09:17 INSP Inspire Medical $249.33 / +5.91 (+2.43%) Lake Street analyst Frank… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events INSP Inspire Medical $249.33 / +5.91 (+2.43%) 12/20/22 Inspire Medical publishes inaugural ESG summary report 09/14/22 Inspire Medical announces updates from ISSS, AAO-HNSF meetings 08/15/22 Inspire Medical appoints Ezgi Yagci as VP, investor relations INSP Inspire Medical $249.33 / +5.91 (+2.43%) 07:45 Today Truist Inspire Medical price target raised to $330 from $310 at Truist 04:30 Today Piper Sandler Inspire Medical price target raised to $305 from $300 at Piper Sandler 01/31/23 Truist Inspire Medical price target raised to $310 from $308 at Truist 01/31/23 Lake Street CVRx initiated with a Buy at Lake Street INSP Inspire Medical $249.33 / +5.91 (+2.43%) 02/07/23 Inspire Medical reports Q4 EPS 10c, consensus (57c) 01/09/23 Inspire Medical sees FY22 revenue $407.5M-$407.9M, consensus $387.61M 01/09/23 Inspire Medical sees Q4 revenue $137.5M-$137.9M, consensus $117.03M 11/01/22 Inspire Medical raises FY22 revenue view to $384M-$388M from $354M-$362M 12 Aug INSP Inspire Medical $249.33 / +5.91 (+2.43%) 01/31/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/01/23 Inspire Medical 03/02/23 Inspire Medical 03/02/23 Inspire Medical
Hot Stocks	Avantax appoints Melissa Loner as CCO » 09:16 02/08/23 02/08 09:16 02/08/23 09:16 AVTA Avantax $29.20 / +0.365 (+1.27%) Avantax announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Events Options AVTA Avantax $29.20 / +0.365 (+1.27%) 01/27/23 Avantax commences modified dutch auction tender offer to repurchase up to $250M 01/26/23 Avantax announces appointment of Bailey as CLO, Corporate Secretary 01/25/23 Blucora to change corporate name to Avantax 02/16/23 Avantax - AVTA AVTA Avantax $29.20 / +0.365 (+1.27%) 01/26/23 Two new option listings and one option delisting on January 26th
Recommendations	Catalent price target raised to $85 from $73 at RBC Capital » 09:16 02/08/23 02/08 09:16 02/08/23 09:16 CTLT Catalent $71.55 / +4.545 (+6.78%) RBC Capital analyst Sean… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CTLT Catalent $71.55 / +4.545 (+6.78%) 02/06/23 Catalent rises 20.2% 02/06/23 Catalent rises 23.0% 02/06/23 Catalent rises 23.7% 02/05/23 Fly Intel: Top five weekend stock stories CTLT Catalent $71.55 / +4.545 (+6.78%) 08:22 Today BofA Catalent price target raised to $78 from $60 at BofA 07:10 Today Baird Catalent price target raised to $82 from $75 at Baird 05:25 Today Barclays Catalent price target raised to $82 from $58 at Barclays 02/06/23 Jefferies Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple CTLT Catalent $71.55 / +4.545 (+6.78%) 02/07/23 Catalent sees FY23 revenue $4.63B-$4.88B, consensus $4.69B 02/07/23 Catalent reports Q2 adjusted EPS 67c, consensus 69c 11/01/22 Catalent cuts FY23 revenue view to $4.625B-$4.875B from $4.975B-$5.225B 11/01/22 Catalent reports Q1 adjusted EPS 34c, consensus 56c CTLT Catalent $71.55 / +4.545 (+6.78%) 02/04/23 Danaher has expressed takeover interest in Catalent, Bloomberg says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/08/22 Glasshouse Research short Catalent, cites 'accounting red flags' 08/11/22 Repligen turned down bid from Catalent, Street Insider says CTLT Catalent $71.55 / +4.545 (+6.78%) 02/06/23 What You Missed On Wall Street On Monday 02/06/23 What You Missed On Wall Street This Morning 02/06/23 Fly Intel: Pre-market Movers 12/08/22 What You Missed On Wall Street On Thursday CTLT Catalent $71.55 / +4.545 (+6.78%) 02/06/23 Early notable gainers among liquid option names on February 6th 01/11/23 Early notable gainers among liquid option names on January 11th 12/09/22 Early notable gainers among liquid option names on December 9th
Hot Stocks	NeuroSense receives approval in Germany to enroll patients in Paradigm study » 09:16 02/08/23 02/08 09:16 02/08/23 09:16 NRSN NeuroSense $1.55 / -0.02 (-1.27%) NeuroSense Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News NRSN NeuroSense $1.55 / -0.02 (-1.27%) 02/06/23 NeuroSense announces Canada approved patient enrollment for PARADIGM study 01/19/23 NeuroSense reports final results from Alzheimer's combination platform study 11/16/22 NeuroSense gets regulatory approval to commence enrollment in ALS study in Italy 11/15/22 NeuroSense's Phase 2b study in ALS receives FDA clearance
Recommendations	Illumina price target lowered to $235 from $285 at Stifel » 09:15 02/08/23 02/08 09:15 02/08/23 09:15 ILMN Illumina $215.71 / +7.085 (+3.40%) Stifel analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ILMN Illumina $215.71 / +7.085 (+3.40%) 02/02/23 Guardant Health 'pleased' with ruling in Illumina case 02/01/23 Illumina appoints Joydeep Goswami as CFO 01/09/23 Illumina, Nashville Biosciences announce sequencing agreement with Amgen 12/05/22 European Commission says Illumina has to unwind Grail acquisition ILMN Illumina $215.71 / +7.085 (+3.40%) 08:00 Today RBC Capital Illumina price target raised to $303 from $284 at RBC Capital 07:58 Today BofA Illumina price target raised to $230 from $210 at BofA 05:32 Today Barclays Illumina price target lowered to $150 from $160 at Barclays 01/27/23 Piper Sandler Illumina price target lowered to $290 from $300 at Piper Sandler ILMN Illumina $215.71 / +7.085 (+3.40%) 02/07/23 Illumina sees FY23 adjusted EPS $1.25-$1.50, consensus $1.98 02/07/23 Illumina reports Q4 adjusted EPS 14c, consensus 10c 02/07/23 Notable companies reporting after market close 11/03/22 Illumina sees FY22 adjusted EPS $2.35-$2.50, consensus $2.78 ILMN Illumina $215.71 / +7.085 (+3.40%) 01/11/23 Illumina to face EU fine of 10% of turnover due to Grail deal, Reuter says 01/11/23 Illumina facing EU fine of 10% turnover over Grail deal, Reuters says 10/08/22 Illumina should be bought before stock drives higher, Barron's says 09/29/22 Illumina launches line of high-end DNA sequences, Statnews reports ILMN Illumina $215.71 / +7.085 (+3.40%) 02/07/23 Fly Intel: After-Hours Movers 02/03/23 Sell these stocks now, proven algorithm says 01/11/23 What You Missed On Wall Street On Wednesday 01/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ILMN Illumina $215.71 / +7.085 (+3.40%) 02/07/23 Illumina options imply 6.4% move in share price post-earnings 10/04/22 Early notable gainers among liquid option names on October 4th 09/28/22 Early notable gainers among liquid option names on September 28th 09/06/22 Early notable gainers among liquid option names on September 6th
Hot Stocks	TELEMEDICUS Inc. trading halted, news pending 09:13 02/08/23 02/08 09:13 02/08/23 09:13 TMDI Titan Medical / + ShowHide Related Items >><< Company News Street Research Earnings TMDI Titan Medical / + 12/28/22 Titan Medical receives noncompliance notification from Nasdaq 12/13/22 Titan Medical announces USPTO granted patent covering user experience 12/07/22 Titan Medical suspends special meeting of shareholders 12/06/22 Titan Medical U.S. subsidiary temporarily furloughs 40 employees TMDI Titan Medical / + 03/25/22 Oppenheimer Titan Medical downgraded to Perform from Outperform at Oppenheimer 03/25/22 Oppenheimer Titan Medical downgraded to Perform from Outperform at Oppenheimer TMDI Titan Medical / + 11/10/22 Titan Medical reports Q3 EPS (9c) vs (8c) last year 08/11/22 Titan Medical reports Q2 EPS (10c) vs. (1c) last year
Upgrade	Guangshen Railway upgraded to Buy from Hold at Jefferies » 09:11 02/08/23 02/08 09:11 02/08/23 09:11 GNGYF Guangshen Railway / + Jefferies analyst Hengli… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	EnWave announces partner plans to launch new seafood snack pack in 2023 » 09:10 02/08/23 02/08 09:10 02/08/23 09:10 NWVCF EnWave / + EnWave Corporatio… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NWVCF EnWave / + 01/23/23 EnWave provides corporate update on operating subsidiary 01/18/23 EnWave signs commercial license with Canadian cannabis company 12/06/22 EnWave signs Technology Evaluation, License Option Agreement with egg supplier 12/01/22 EnWave announces CFO Henriques to leave, Murray to succeed NWVCF EnWave / + 06/01/22 Raymond James EnWave downgraded to Market Perform from Outperform at Raymond James NWVCF EnWave / + 12/16/22 EnWave reports Q4 EPS (C$0.02) vs. (C$0.01) last year
Hot Stocks	Celanese expanding portfolio of sustainable products across Acetyl Chain » 09:10 02/08/23 02/08 09:10 02/08/23 09:10 CE Celanese $123.94 / +2.02 (+1.66%) Celanese announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CE Celanese $123.94 / +2.02 (+1.66%) 11/14/22 Berkshire Hathaway adds TSMC, exits STORE Capital in Q3 11/01/22 DuPont completes M&M divestiture to Celanese 10/26/22 Celanese lifts force majeure on certain Western hemisphere Acetyl Chain products 10/19/22 Celanese raises quarterly cash dividend to 70c from 68c per share CE Celanese $123.94 / +2.02 (+1.66%) 01/05/23 Barclays Axalta Coating price target raised to $30 from $28 at Barclays 01/04/23 RBC Capital Celanese upgraded to Outperform from Sector Perform at RBC Capital 12/19/22 Barclays Celanese price target raised to $150 from $133 at Barclays 12/15/22 Citi Celanese price target raised to $111 from $96 at Citi CE Celanese $123.94 / +2.02 (+1.66%) 11/03/22 Celanese sees Q4 adjusted EPS $1.50-$2.00, consensus $3.10 11/03/22 Celanese reports Q3 adjusted EPS $3.94, consensus $3.98 02/24/23 Celanese - CE

Hot Stocks	LivaNova announces limited commercial release for Essenz Perfusion System » 09:09 02/08/23 02/08 09:09 02/08/23 09:09 LIVN LivaNova $55.67 / +0.88 (+1.61%) LivaNova announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events LIVN LivaNova $55.67 / +0.88 (+1.61%) 12/13/22 LivaNova announces receipt of close-out warning letter from FDDA 11/17/22 LivaNova receives 510 clearance for ECMO from FDA for LifeSPARC 11/14/22 Greenlight takes new stake in Intel, exits position in Atlas Air 08/29/22 LivaNova says committee advises RECOVER trial should continue on LIVN LivaNova $55.67 / +0.88 (+1.61%) 02/07/23 Piper Sandler LivaNova tells Piper FDA clinical trial website update incorrect 12/21/22 Barclays LivaNova initiated with an Equal Weight at Barclays 11/02/22 Piper Sandler LivaNova price target lowered to $84 from $94 at Piper Sandler 08/03/22 Piper Sandler LivaNova price target lowered to $94 from $99 at Piper Sandler LIVN LivaNova $55.67 / +0.88 (+1.61%) 11/02/22 LivaNova backs FY22 adjusted EPS view $2.25-$2.45, consensus $2.30 11/02/22 LivaNova reports Q3 adjusted EPS 58c, consensus 54c 02/22/23 LivaNova - LIVN
Hot Stocks	CVS Health says Oak Street Health deal has long term growth, earnings power » 09:09 02/08/23 02/08 09:09 02/08/23 09:09 CVS CVS Health $86.02 / +0.77 (+0.90%) , OSH Oak Street Health $33.67 / +7.64 (+29.35%) Expects to maintain… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options CVS OSH CVS CVS Health $86.02 / +0.77 (+0.90%) 08:37 Today CVS Health says ability to generate cash 'remains strong' 08:19 Today CVS Health says entering 2023 with 'great momentum' 07:42 Today CVS Health sees FY23 CapEx $2.8B-$3B 07:40 Today CVS Health sees FY23 Health Care Benefits revenue $101.4B-$102.9B OSH Oak Street Health $33.67 / +7.64 (+29.35%) 06:03 Today CVS Health to acquire Oak Street Health for $39 per share 02/07/23 Oak Street Health rises 30.0% 02/07/23 Oak Street Health notes policy not to comment on unusual market activity 02/07/23 Oak Street Health rises 31.3% CVS OSH CVS CVS Health $86.02 / +0.77 (+0.90%) 08:07 Today Piper Sandler Oak Street Health downgraded to Neutral from Overweight at Piper Sandler 07:36 Today Stifel Oak Street Health downgraded to Hold from Buy at Stifel 02/07/23 Stifel Oak Street Health price target raised to $39 from $35 at Stifel 02/07/23 Piper Sandler Oak Street 'particularly attractive' in current environment, says Piper Sandler OSH Oak Street Health $33.67 / +7.64 (+29.35%) 08:26 Today Evercore ISI Oak Street Health downgraded to In Line from Outperform at Evercore ISI 08:07 Today Piper Sandler Oak Street Health downgraded to Neutral from Overweight at Piper Sandler 07:36 Today Stifel Oak Street Health downgraded to Hold from Buy at Stifel 02/07/23 Stifel Oak Street Health price target raised to $39 from $35 at Stifel CVS OSH CVS CVS Health $86.02 / +0.77 (+0.90%) 07:37 Today CVS Health sees FY23 revenue $332.7B-$338.5B, consensus $325.11B 06:33 Today CVS Health reports Q4 adjusted EPS $1.99, consensus $1.92 06:05 Today CVS Health sees FY24 adjusted EPS $9.00, FY25 adjusted EPS $10.00 06:04 Today CVS Health backs FY23 adjusted EPS view $8.70-$8.90, consensus $8.86 OSH Oak Street Health $33.67 / +7.64 (+29.35%) 01/09/23 Oak Street Health sees FY23 revenue $3.0B-$3.15B, consensus $3.05B 01/09/23 Oak Street Health raises FY22 revenue view to at or above $2.155B 11/07/22 Oak Street Health reports Q3 EPS (56c), consensus (61c) 17 Aug CVS OSH CVS CVS Health $86.02 / +0.77 (+0.90%) 02/06/23 CVS Health near deal to acquire Oak Street Health for $10.5B, WSJ says 02/06/23 CVS Health near deal to acquire Oak Street Health for $10.5B, WSJ says 01/27/23 Cigna sues CVS Health, Amy Bricker for violating noncompete, Bloomberg Law says 01/19/23 Rite Aid plans to provide abortion pill in some stores, Bloomberg reports OSH Oak Street Health $33.67 / +7.64 (+29.35%) 02/06/23 CVS Health near deal to acquire Oak Street Health for $10.5B, WSJ says 02/06/23 CVS Health near deal to acquire Oak Street Health for $10.5B, WSJ says 01/09/23 CVS exploring $10B-plus takeover of Oak Street, Bloomberg says 01/09/23 CVS Health exploring acquisition of Oak Street Health, Bloomberg reports CVS OSH CVS CVS Health $86.02 / +0.77 (+0.90%) 08:59 Today Fly Intel: Pre-market Movers 02/07/23 What You Missed On Wall Street On Tuesday 02/07/23 What You Missed On Wall Street This Morning 02/07/23 Fly Intel: Pre-market Movers OSH Oak Street Health $33.67 / +7.64 (+29.35%) 08:59 Today Fly Intel: Pre-market Movers 02/07/23 What You Missed On Wall Street On Tuesday 02/07/23 What You Missed On Wall Street This Morning 02/07/23 Fly Intel: Pre-market Movers 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today CVS Health - CVS CVS OSH CVS CVS Health $86.02 / +0.77 (+0.90%) 11/28/22 CVS Health put volume heavy and directionally bearish 11/02/22 Unusually active option classes on open November 2nd 10/19/22 Unusually active option classes on open October 19th 09/13/22 CVS Health call volume above normal and directionally bullish OSH Oak Street Health $33.67 / +7.64 (+29.35%) 02/06/23 Oak Street Health put volume heavy and directionally bearish 01/24/23 Oak Street Health call volume above normal and directionally bullish 01/10/23 Unusually active option classes on open January 10th 11/07/22 Oak Street Health options imply 13.2% move in share price post-earnings
Hot Stocks	Vital Farms appoints Wrede as Chief Financial Officer » 09:08 02/08/23 02/08 09:08 02/08/23 09:08 VITL Vital Farms $16.87 / -0.18 (-1.06%) Vital Farms is adding a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings VITL Vital Farms $16.87 / -0.18 (-1.06%) 09/30/22 Vital Farms announces 'Keeping it Bullsh*t-Free' campaign 08/25/22 Vital Farms announces launch of new Restorative eggs VITL Vital Farms $16.87 / -0.18 (-1.06%) 09/30/22 UBS Vital Farms initiated with a Buy at UBS 07/20/22 Morgan Stanley Vital Farms upgraded to Overweight from Equal Weight at Morgan Stanley 05/06/22 BMO Capital Vital Farms price target lowered to $15 from $20 at BMO Capital VITL Vital Farms $16.87 / -0.18 (-1.06%) 11/03/22 Vital Farms sees 2022 revenue over $340M, consensus $345.03M 11/03/22 Vital Farms reports Q3 EPS 2c, consensus 1c
Initiation	Alithya Group initiated with an Outperform at Barrington » 09:07 02/08/23 02/08 09:07 02/08/23 09:07 ALYA Alithya Group $1.76 / -0.01 (-0.56%) Barrington analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events ALYA Alithya Group $1.76 / -0.01 (-0.56%) 01/12/23 Alithya Group appoints Bernard Dockrill as new COO 12/14/22 Zscaler, Alithya Group announce partnership 10/18/22 Alithya Group partners with OneWorldSIS for higher education solutions 10/11/22 Alithya Group enters two-phased agreement with Canadian University ALYA Alithya Group $1.76 / -0.01 (-0.56%) 12/21/22 Scotiabank Alithya Group assumed with a Sector Perform at Scotiabank 11/11/22 BMO Capital Alithya Group price target lowered to C$3 from C$3.50 at BMO Capital 10/28/22 National Bank Alithya Group initiated with a Sector Perform at National Bank 09/07/22 BMO Capital Alithya Group initiated with a Market Perform at BMO Capital 02/14/23 Alithya Group - ALYA
Earnings	Natural Health Trends reports Q4 EPS 2c vs. 2c last year » 09:07 02/08/23 02/08 09:07 02/08/23 09:07 NHTC Natural Health Trends $4.77 / -0.07 (-1.45%) Reports Q4 revenue $12.5M… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Earnings Events NHTC Natural Health Trends $4.77 / -0.07 (-1.45%) 11/02/22 Natural Health Trends reprts Q3 EPS 0c vs. 4c last year 11:30 Today Natural Health Trends - NHTC
Hot Stocks	Digital subsidiary announces Goodcents' plan to maintain certified clean progam » 09:07 02/08/23 02/08 09:07 02/08/23 09:07 DGLY Digital Ally $5.75 / -1.456 (-20.21%) Shield Products, a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News DGLY Digital Ally $5.75 / -1.456 (-20.21%) 02/07/23 Digital Ally announces 1-for-20 reverse stock split 01/24/23 Digital Ally announces order of its complete video ecosystem 12/20/22 Digital Ally announces deal with MetLife Stadium 12/15/22 Digital Ally to complete spin-off of Kustom Entertainment in 1H23
Recommendations	Stephens keeps Equal Weight on Green Plains, estimates under review after Q4 » 09:06 02/08/23 02/08 09:06 02/08/23 09:06 GPRE Green Plains $33.96 / -0.24 (-0.70%) Stephens analyst Ben… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events GPRE Green Plains $33.96 / -0.24 (-0.70%) 01/31/23 Green Plains spikes over 10% after investor Ancora urges 'full sale' 01/31/23 United Airlines, Green Plains form Joint Venture for ethanol aviation fuel 01/31/23 Green Plains holder Ancora urges company for 'full sale' for shareholder value 09/22/22 Green Plains CFO transitions to new role, Jim Stark to succeed GPRE Green Plains $33.96 / -0.24 (-0.70%) 01/17/23 Stephens Green Plains downgraded to Equal Weight from Overweight at Stephens 12/14/22 UBS Green Plains initiated with a Buy at UBS 12/13/22 UBS Green Plains initiated with a Buy at UBS 10/24/22 BofA Green Plains price target lowered to $35 from $43 at BofA GPRE Green Plains $33.96 / -0.24 (-0.70%) 07:35 Today Green Plains reports Q4 EPS (66c), consensus (25c) 11/03/22 Green Plains reports Q3 EPS ($1.27), consensus (11c) GPRE Green Plains $33.96 / -0.24 (-0.70%) 11/30/22 EPA to propose boost in biofuel quotas, Reuters reports 11/30/22 President Biden plans to boost biofuel quotas for next 3 years, Bloomberg says GPRE Green Plains $33.96 / -0.24 (-0.70%) 01/31/23 What You Missed On Wall Street On Tuesday 01/31/23 What You Missed On Wall Street This Morning 03/12/23 35th Annual Roth Conference 09:00 Today Green Plains - GPRE
Earnings	Pioneer Power expects FY22 revenue to exceed $27.5M » 09:06 02/08/23 02/08 09:06 02/08/23 09:06 PPSI Pioneer Power $2.89 / -0.08 (-2.69%) Pioneer Power Solutions… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research PPSI Pioneer Power $2.89 / -0.08 (-2.69%) 01/09/23 Pioneer Power receives additional orders for e-Boost mobile EV charging solution 12/01/22 Pioneer Power wins $5M E-Bloc order from California-based water utility 10/12/22 Pioneer Power awarded $8M purchase order for its flagship E-Bloc solution PPSI Pioneer Power $2.89 / -0.08 (-2.69%) 10/12/22 H.C. Wainwright Pioneer Power contract shows share gains continue, says H.C. Wainwright
Recommendations	Model N price target raised to $52 from $45 at Truist » 09:06 02/08/23 02/08 09:06 02/08/23 09:06 MODN Model N $40.82 / +0.555 (+1.38%) , ABBV AbbVie $145.14 / +0.12 (+0.08%) , MRNA Moderna $171.07 / +0.755 (+0.44%) Truist analyst Terry… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MODN ABBV MRNA MODN Model N $40.82 / +0.555 (+1.38%) 12/20/22 Model N falls -7.1% 08/10/22 Model N rises 29.3% 08/10/22 Model N rises 22.8% ABBV AbbVie $145.14 / +0.12 (+0.08%) 01/10/23 AbbVie and Anima Biotech collaborate for mRNA modulators discovery 01/06/23 AbbVie, Immunome enter collaboration to discover novel antibody-target pairs 01/06/23 AbbVie, Immunome announce strategic collaboration 12/21/22 Washington state AG files lawsuits against pharmacy chains over opioid crisis MRNA Moderna $171.07 / +0.755 (+0.44%) 02/03/23 Personalis, Moderna announce new agreement to leverage NeXT Platform 01/30/23 Moderna granted Breakthrough Therapy Designation for mRNA-1345 01/17/23 Moderna jumps 7% to $203.21 after announcing data from mRNA-13 efficacy trial 01/17/23 Moderna announces data from efficacy trial of mRNA-1345 targeting RSV MODN ABBV MRNA MODN Model N $40.82 / +0.555 (+1.38%) 11/09/22 Needham Model N price target raised to $42 from $34 at Needham 11/09/22 Truist Model N price target raised to $45 from $35 at Truist 11/09/22 Craig-Hallum Model N price target raised to $42 from $34 at Craig-Hallum 11/09/22 JMP Securities Model N price target raised to $46 from $39 at JMP Securities ABBV AbbVie $145.14 / +0.12 (+0.08%) 01/26/23 JPMorgan AbbVie recent weakness a buying opportunity, says JPMorgan 01/05/23 Truist AbbVie price target raised to $180 from $160 at Truist 11/17/22 Credit Suisse AbbVie initiated with an Outperform at Credit Suisse 11/08/22 Societe Generale AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds MRNA Moderna $171.07 / +0.755 (+0.44%) 07:10 Today Baird Catalent price target raised to $82 from $75 at Baird 02/06/23 Needham Personalis upgraded to Buy at Needham on cost reductions, biopharma potential 01/25/23 Cowen Moderna price target raised to $150 from $130 at Cowen 01/18/23 Chardan Moderna price target raised to $208 from $191 at Chardan MODN ABBV MRNA MODN Model N $40.82 / +0.555 (+1.38%) 02/07/23 Model N sees FY23 EPS 90c-97c, consensus 93c 02/07/23 Model N sees Q2 EPS 15c-18c, consensus 21c 02/07/23 Model N reports Q1 EPS 23c, consensus 22c 11/09/22 Model N sees FY23 revenue 90c-97c, consensus 77c ABBV AbbVie $145.14 / +0.12 (+0.08%) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M 10/28/22 AbbVie sees FY22 revenue approximately $58.2B, consensus $59.92B 10/28/22 AbbVie sees Q4 adjusted EPS $3.65-$3.69, consensus $3.75 10/28/22 AbbVie narrows FY22 adjusted EPS view to $13.84-$13.88 from $13.76-$13.96 MRNA Moderna $171.07 / +0.755 (+0.44%) 11/03/22 Moderna reports Q3 EPS $2.53, consensus $3.29 11/02/22 Notable companies reporting before tomorrow's open 11/02/22 Notable companies reporting before tomorrow's open ABBV MRNA ABBV AbbVie $145.14 / +0.12 (+0.08%) 02/06/23 AbbVie looking for next hit drug after competitors target Humira, WSJ reports 01/31/23 AbbVie's Humira drug faces competition in the U.S., FT reports 12/03/22 Buy AbbVie, stock still worth owning even as Humira fades, Barron's says 11/16/22 Optum Rx puts biosimilars on formulary against AbbVie's Humira, Bloomberg says MRNA Moderna $171.07 / +0.755 (+0.44%) 02/01/23 Novavax refuses to refund $700M for COVID shots never delivered, NY Times says 01/27/23 FDA advisors recommend replacing original COVID-19 vaccine, CNBC reports 01/09/23 Moderna considering $110-$130 for COVID shot, similar to Pfizer's, WSJ says 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says MODN ABBV MRNA MODN Model N $40.82 / +0.555 (+1.38%) 02/07/23 Fly Intel: After-Hours Movers 11/09/22 What You Missed On Wall Street On Wednesday 11/09/22 What You Missed On Wall Street This Morning ABBV AbbVie $145.14 / +0.12 (+0.08%) 02/06/23 What You Missed On Wall Street On Monday 02/06/23 What You Missed On Wall Street This Morning 01/31/23 What You Missed On Wall Street On Tuesday 01/31/23 What You Missed On Wall Street This Morning MRNA Moderna $171.07 / +0.755 (+0.44%) 01/18/23 What You Missed On Wall Street On Wednesday 01/18/23 What You Missed On Wall Street This Morning 01/17/23 Fly Intel: After-Hours Movers 01/10/23 What You Missed On Wall Street On Tuesday 02/16/23 2023 Tandem Meetings of ASTCG and CIBMTR 02/24/23 Annual Meeting of AAAAI 2023 03/06/23 Technology Conference 02/09/23 AbbVie - ABBV 02/23/23 Moderna - MRNA 05/21/23 PDUFA Date for Epcoritamab (DuoBody-CD3xCD20) 02/16/23 Model N, Inc. ABBV MRNA ABBV AbbVie $145.14 / +0.12 (+0.08%) 01/18/23 Unusually active option classes on open January 18th 10/28/22 Unusually active option classes on open October 28th 08/19/22 Unusually active option classes on open August 19th MRNA Moderna $171.07 / +0.755 (+0.44%) 01/30/23 Moderna put volume heavy and directionally bearish 01/18/23 Early notable gainers among liquid option names on January 18th 01/18/23 Unusually active option classes on open January 18th 12/30/22 Unusually active option classes on open December 30th
Hot Stocks	NFL selects Verizon Business for private wireless solution » 09:05 02/08/23 02/08 09:05 02/08/23 09:05 VZ Verizon $40.56 / -0.74 (-1.79%) Verizon, an Official… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VZ Verizon $40.56 / -0.74 (-1.79%) 08:34 Today Verizon named NFL's official private wireless network 02/07/23 Verizon, Team Penske to continue storied partnership 02/07/23 Verizon achieves upload speeds surpassing 1 Gbps 01/24/23 NYSE sees unusual number of halted stocks at open due to exchange issues VZ Verizon $40.56 / -0.74 (-1.79%) 02/07/23 LightShed Partners AT&T downgraded to Neutral from Buy at LightShed Partners 02/06/23 MoffettNathanson T-Mobile downgraded at MoffettNathanson amid 'great deceleration' 01/26/23 Citi Verizon price target raised to $42 from $39 at Citi 01/25/23 Cowen Verizon price target lowered to $49 from $55 at Cowen VZ Verizon $40.56 / -0.74 (-1.79%) 01/24/23 Verizon sees 2023 adjusted EPS $4.55-$4.85, consensus $4.99 01/24/23 Verizon reports Q4 adjusted EPS $1.19, consensus $1.19 01/23/23 Notable companies reporting before tomorrow's open 01/23/23 Notable companies reporting before tomorrow's open VZ Verizon $40.56 / -0.74 (-1.79%) 01/10/23 Best Buy-owned Lively faces complaints after 3G shutdown, WSJ reports 12/20/22 FCC partisan deadlock shields wireless companies from $200M fine, WSJ reports 08/27/22 T-Mobile replaced Verizon atop wireless world, time to buy stock, Barron's says VZ Verizon $40.56 / -0.74 (-1.79%) 02/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/24/23 What You Missed On Wall Street On Tuesday 01/24/23 What You Missed On Wall Street This Morning 01/24/23 Fly Intel: Pre-market Movers 04/25/23 Verizon - VZ VZ Verizon $40.56 / -0.74 (-1.79%) 12/15/22 Verizon call volume above normal and directionally bullish 12/15/22 Early notable gainers among liquid option names on December 15th 12/15/22 Unusually active option classes on open December 15th 10/21/22 Unusually active option classes on open October 21st

Recommendations	Haemonetics price target raised to $103 from $94 at Barrington » 09:05 02/08/23 02/08 09:05 02/08/23 09:05 HAE Haemonetics $82.55 / -5.435 (-6.18%) Barrington analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HAE Haemonetics $82.55 / -5.435 (-6.18%) 01/09/23 ViewRay CFO to step down, William Burke to succeed 09/12/22 Haemonetics earns CE mark certification for Vascade, Vascade MVP 08/11/22 Haemonetics shares rose 9% on Wednesday following Q1 results HAE Haemonetics $82.55 / -5.435 (-6.18%) 06:39 Today Mizuho Haemonetics price target raised to $115 from $110 at Mizuho 01/24/23 Mizuho Haemonetics price target raised to $110 from $100 at Mizuho 12/12/22 Citi Haemonetics price target raised to $92 from $88 at Citi 11/08/22 Barrington Haemonetics price target raised to $94 from $88 at Barrington HAE Haemonetics $82.55 / -5.435 (-6.18%) 02/07/23 Haemonetics raises FY23 adjusted EPS view to $2.90-$3.00 from $2.70-$3.00 02/07/23 Haemonetics reports Q3 adjusted EPS 85c, consensus 80c 11/07/22 Haemonetics raises FY23 adjusted EPS view to $2.70-$3.00 from $2.60-$2.90 11/07/22 Haemonetics reports Q2 adjusted EPS 83c, consensus 67c HAE Haemonetics $82.55 / -5.435 (-6.18%) 11/07/22 Fly Intel: Pre-market Movers 06/14/23 Haemonetics
Hot Stocks	Nano Dimension announces new patent for cloud manufacturing platform » 09:05 02/08/23 02/08 09:05 02/08/23 09:05 NNDM Nano Dimension $2.61 / -0.085 (-3.15%) Nano Dimension announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Events Options NNDM Nano Dimension $2.61 / -0.085 (-3.15%) 02/01/23 Nano Dimension receives purchase order from U.S. government defense supplier 01/31/23 Nano Dimension issues special message to shareholders 01/30/23 Nano Dimension adopts limited duration shareholder rights plan 01/30/23 Nano Dimension rejects Murchinson request for special meeting of shareholders NNDM Nano Dimension $2.61 / -0.085 (-3.15%) 01/24/23 Nano Dimension reports Q4 revenue $12.1M, up 61% vs. 4Q21 12/01/22 Nano Dimension reports Q3 EPS (26c) vs. (7c) last year 10/24/22 Nano Dimension sees Q3 revenue $10M 09/01/22 Nano Dimension rports Q2 EPS (15c) vs. (5c) last year 03/30/23 Nano Dimension - NNDM NNDM Nano Dimension $2.61 / -0.085 (-3.15%) 01/20/23 Largest borrow rate increases among liquid names
Recommendations	Enanta price target raised to $68 from $56 at H.C. Wainwright » 09:03 02/08/23 02/08 09:03 02/08/23 09:03 ENTA Enanta $54.46 / +1.75 (+3.32%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ENTA Enanta $54.46 / +1.75 (+3.32%) 11/09/22 Enanta begins Phase 2 clinical trial of protease inhibitor EDP-235 for Covid 10/17/22 Enanta doses first subject in Phase 1 study of EDP-323 10/03/22 Enanta initiates EDP-938 trial ENTA Enanta $54.46 / +1.75 (+3.32%) 12/09/22 H.C. Wainwright Enanta initiated with a Buy at H.C. Wainwright 11/22/22 RBC Capital Enanta price target lowered to $54 from $65 at RBC Capital 10/17/22 Piper Sandler Enanta trial start marks fourth in RSV franchise, says Piper Sandler 08/10/22 Oppenheimer Enanta price target raised to $59 from $53 at Oppenheimer ENTA Enanta $54.46 / +1.75 (+3.32%) 02/07/23 Enanta Pharmaceuticals reports Q1 EPS ($1.39), consensus ($1.59) 11/21/22 Enanta reports Q4 EPS ($1.27), consensus ($1.35) 08/08/22 Enanta reports Q3 EPS ($1.53), consensus ($1.39) 02/16/23 Enanta 02/28/23 Enanta 03/02/23 Enanta Pharmaceuticals, Inc.
Hot Stocks	BioRestorative announces notice of allowance by EPO for ThermoStem program » 09:03 02/08/23 02/08 09:03 02/08/23 09:03 BRTX BioRestorative Therapies $3.09 / -0.01 (-0.32%) BioRestorative Therapies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events BRTX BioRestorative Therapies $3.09 / -0.01 (-0.32%) 12/06/22 BioRestorative Therapies announces SBIR Phase I grant 12/05/22 BioRestorative enters agreement with Regenexx, granted exclusive license rights BRTX BioRestorative Therapies $3.09 / -0.01 (-0.32%) 12/07/22 Roth Capital BioRestorative Therapies initiated with a Buy at Roth Capital 09/28/22 Maxim BioRestorative Therapies initiated with a Buy at Maxim 03/12/23 35th Annual Roth Conference
Recommendations	Trane price target raised to $200 from $185 at Argus » 09:03 02/08/23 02/08 09:03 02/08/23 09:03 TT Trane $180.43 / -4.53 (-2.45%) Argus analyst John Eade… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events TT Trane $180.43 / -4.53 (-2.45%) 01/24/23 Trane rises 8.2% 01/24/23 Trane Technologies trading resumes 01/24/23 Trane Technologies trading halted, volatility trading pause 11/15/22 Trane commits to low-carbon steel purchases from Nucor, U.S. Steel TT Trane $180.43 / -4.53 (-2.45%) 02/03/23 Deutsche Bank Trane price target raised to $184 from $170 at Deutsche Bank 02/03/23 RBC Capital Trane price target raised to $177 from $164 at RBC Capital 02/03/23 Mizuho Trane price target raised to $185 from $175 at Mizuho 01/26/23 OTR Global U.S. commercial HVAC equipment view upgraded at OTR Global TT Trane $180.43 / -4.53 (-2.45%) 02/02/23 Trane sees 2023 adjusted EPS $8.20-$8.50, consensus $7.89 02/02/23 Trane reports Q4 adjusted EPS $1.82, consensus $1.65 11/02/22 Trane raises FY22 adjusted EPS view to $7.15-$7.20 from $7.05-$7.15 11/02/22 Trane reports Q3 adjusted EPS $2.27, consensus $2.12 02/15/23 44th Annual Aerospace/Defense & Industrials Conference

Events

Earnings calls, analyst events, roadshows and more

CMP
Today at 09:30

Compass Minerals - CMP Conference Calls
TWTR
Today at 10:00

Protecting Speech from Gov't Interference Part I Government Event

2154 Rayburn House Office Building, Washington, D.C.
Today at 10:00

Wholesale Inventories (Preliminary) M/M: December 2022 Government Event
BAM
Today at 10:00

Brookfield Asset Management - BAM Conference Calls
EHC
Today at 10:00

Encompass Health - EHC Conference Calls
KREF
Today at 10:00

KKR Real Estate Finance - KREF Conference Calls
CNO
Today at 10:00

CNO Financial - CNO Conference Calls
RSVR
Today at 10:00

Reservoir Media - RSVR Conference Calls
VOYA
Today at 10:00

Voya Financial - VOYA Conference Calls
CSPI
Today at 10:00

CSP Inc. - CSPI Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	BLNK X BLNK Blink Charging Spot Secondary Managers: Barclays Priced at: $12.00 8.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	CVAC X CVAC CureVac Secondary Managers: Goldman Sachs, Jefferies, SVB Securities & Kempen Priced at: $9.25 27.027M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DT X DT Dynatrace Spot Secondary Managers: BofA Priced at: $45.55 15M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan, Goldman Sachs & Morgan Stanley Priced at: $140.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LBPH X LBPH Longboard Pharmaceuticals Spot Secondary Managers: Evercore ISI & Cantor Fitzgerald Priced at: $4.00 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RXST X RXST RxSight Spot Secondary Managers: BofA Priced at: $12.50 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SINT X SINT Sintx Technologies Spot Secondary Managers: Maxim Priced at: $5.60 2.15M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial STAF X STAF Staffing 360 Solutions Spot Secondary Managers: H.C. Wainwright Priced at: $2.65 1.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TMCI X TMCI Treace Medical Spot Secondary Managers: BTIG Priced at: $21.00 4.76M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial XPOF X XPOF Xponential Fitness Spot Secondary Managers: BofA & Jefferies Priced at: $24.50 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	BFRG X BFRG Bullfrog AI IPO Managers: WallachBeth, Kingswood $6.50 1.32M Shares HSAI X HSAI Hesai IPO Managers: Goldman Sachs, Morgan Stanley & Credit Suisse, Huatai Securities $17.00 - 19.00 9M Shares INTS X INTS Intensity Therapeutics IPO Managers: Benchmark $4.00-4.50 1.778M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NXT X NXT Nextracker IPO Managers: JPMorgan, BofA, Citi & Barclays, Truist, HSBC, BNP Paribas, Mizuho, Scotiabank, KeyBanc $20.00-23.00 23.26M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ENLT X ENLT Enlight Renewable Energy IPO Managers: JPMorgan, BofA & Barclays, Credit Suisse, Wolfe Research, Nomura, HSBC, Roth MKM $20.57 14M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LEWY X LEWY LeeWay Services IPO Managers: ThinkEquity $5.00 1M Shares MLYS X MLYS Mineralys Therapeutics IPO Managers: BofA, Ever Bank, Stifel, Credit Suisse, Guggenheim & Wells Fargo $14.00-16.00 10M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Oatly Group downgraded to Neutral from Outperform at Credit Suisse

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access